Sebia, a company specializing in in vitro diagnostics, and private equity firm Warburg Pincus have entered into exclusive negotiations for Warburg Pincus to acquire a significant minority stake in Sebia. The announcement was made jointly by the two companies on October 16, 2025.
Sebia develops and provides equipment and reagents for disease screening and monitoring, focusing on oncology, diabetes, hemoglobinopathy, autoimmune, infectious diseases, and rare pathologies. The company has a presence in more than 140 countries and operates with a portfolio of proprietary products.
Jean-Marc Chermette, Chief Executive Officer of Sebia, commented on the partnership: “Our mission is to provide powerful tools that translate what is happening in a patient’s body into a readable and interpretable language. We welcome Warburg Pincus as a new partner alongside our existing investor base. Their global healthcare expertise and growth orientation will help accelerate Sebia’s strategy while maintaining our commitment to scientific rigor, product quality and patient impact, helping us deliver for our customers and partners.”
TJ Carella, Managing Director and Global Head of Healthcare, and Jake Strauss, Managing Director and Head of European Healthcare at Warburg Pincus, said: “Sebia is a best-in-class diagnostics platform with differentiated technology and a strong track record of delivering innovative products and solutions to customers and patients worldwide. We are excited to partner with Jean-Marc, the management team, and existing shareholders to support the company’s next phase of growth, including continued advances in diagnostic modalities, scientific excellence and manufacturing capabilities.”
The terms of the proposed transaction have not been disclosed. Sebia will continue to operate independently from its headquarters in Lisses, France. Existing shareholders CVC Funds, La Caisse (formerly CDPQ), and Téthys Invest will remain significant investors.
Completion of the transaction is subject to employee consultation processes and regulatory approvals, with closing expected no earlier than the first quarter of 2026.
Founded in 1967, Sebia expanded its capabilities in autoimmunity diagnostics and infectious diseases following its acquisition of Orgentec, Corgenix, and Arotec in 2021. The company is headquartered in Lisses, France, and operates through 23 direct subsidiaries.
Warburg Pincus, founded in 1966, manages over $86 billion in assets and has invested in more than 1,000 companies globally across various sectors. The firm is headquartered in New York and has offices in major cities worldwide. More information is available at https://www.warburgpincus.com.